EMPA-REG OUTCOME: The Endocrinologist's Point of View
Open Access
- 1 July 2017
- journal article
- review article
- Published by Elsevier BV in The American Journal of Cardiology
- Vol. 120 (1), S48-S52
- https://doi.org/10.1016/j.amjcard.2017.05.010
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Liraglutide and Cardiovascular Outcomes in Type 2 DiabetesThe New England Journal of Medicine, 2016
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary SyndromeThe New England Journal of Medicine, 2015
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 DiabetesThe New England Journal of Medicine, 2015
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes MellitusThe New England Journal of Medicine, 2013
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 DiabetesThe New England Journal of Medicine, 2013
- Glucose Control and Vascular Complications in Veterans with Type 2 DiabetesThe New England Journal of Medicine, 2009
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 DiabetesThe New England Journal of Medicine, 2008
- Effects of Intensive Glucose Lowering in Type 2 DiabetesThe New England Journal of Medicine, 2008
- Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular CausesThe New England Journal of Medicine, 2007
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998